NeuroPace (NPCE) Receives FDA Approval for ECoG Assistant™
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowNeuroPace, Inc. (NPCE) announced on May 29 that it received FDA approval for its ECoG Assistant, an AI-driven feature designed to enhance epilepsy care using long-term intracranial EEG data. The tool is built on 124,450 epileptologist-labeled records, providing physicians with insights through integrated reports and charts. This approval represents a significant step towards practical tools for clinicians according to CEO Joel Becker. The company is also targeting FDA approval for its next-generation patient data platform in the second quarter of 2026.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
